Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$27,000.00

Genomic instability and mitochondrial dysfunction are associated with disease progression in systemic sclerosis

FY 2024-25

Summary
Systemic sclerosis (SSc) is a deadly, incurable disease characterized by immune dysregulation, vasculopathy, and fibrosis. Fibrotic complications associated with SSc result in a mortality rate approaching 40%, a value that rivals most aggressive cancers. The pathogenesis of SSc remains elusive, and treatments targeting the currently defined pathways, such as autoimmune response or fibrosis, have shown little efficacy. Recently, multiple mechanisms, including cellular senescence, genomic instability, and altered metabolism, have been suggested to cause SSc; however, their interplay remains unknown. The aims of this study are to investigate whether mitochondrial dysfunction and genomic mutations in fibroblasts contribute to fibrosis and myofibroblast differentiation in patients with systemic sclerosis (SSc). We will focus on patients with different forms of SSc to assess how these mechanisms vary with disease severity. By using whole exome sequencing (WES) and whole transcriptome sequencing (WTS) on skin biopsies, we will analyze the mutational landscape and transcriptomic changes in skin fibroblasts. Additionally, we will examine mitochondrial DNA copy number and proteins involved in mitochondrial remodeling and biogenesis in fibroblasts and circulating immune cells. Studying mitochondrial dysfunction and genomic mutations in the context of SSc may help identify novel biomarkers that predict disease progression and fibrosis severity. The results of this research could lead to more personalized treatment strategies and ultimately improve patient outcomes. Furthermore, understanding mitochondrial dysfunction in SSc may have broader implications for other fibrotic conditions.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530312
Name
Wang Junqin
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Genomic instability and mitochondrial dysfunction are associated with disease progression in systemic sclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Dna Damage Response (Ddr); Fibrosis; Genomic Instability; Mitochondrial Dysfunction; Systemic Sclerosis (Ssc)
Abstract
Systemic sclerosis (SSc) is a deadly, incurable disease characterized by immune dysregulation, vasculopathy, and fibrosis. Fibrotic complications associated with SSc result in a mortality rate approaching 40%, a value that rivals most aggressive cancers. The pathogenesis of SSc remains elusive, and treatments targeting the currently defined pathways, such as autoimmune response or fibrosis, have shown little efficacy. Recently, multiple mechanisms, including cellular senescence, genomic instability, and altered metabolism, have been suggested to cause SSc; however, their interplay remains unknown. The aims of this study are to investigate whether mitochondrial dysfunction and genomic mutations in fibroblasts contribute to fibrosis and myofibroblast differentiation in patients with systemic sclerosis (SSc). We will focus on patients with different forms of SSc to assess how these mechanisms vary with disease severity. By using whole exome sequencing (WES) and whole transcriptome sequencing (WTS) on skin biopsies, we will analyze the mutational landscape and transcriptomic changes in skin fibroblasts. Additionally, we will examine mitochondrial DNA copy number and proteins involved in mitochondrial remodeling and biogenesis in fibroblasts and circulating immune cells. Studying mitochondrial dysfunction and genomic mutations in the context of SSc may help identify novel biomarkers that predict disease progression and fibrosis severity. The results of this research could lead to more personalized treatment strategies and ultimately improve patient outcomes. Furthermore, understanding mitochondrial dysfunction in SSc may have broader implications for other fibrotic conditions.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Junqin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~